Please login to the form below

Not currently logged in

Quanticate names chief operating officer

Alan Morgan joins the data-focused clinical research organisation

Quanticate Alan MorganLondon-based clinical research organisation Quanticate has appointed Alan Morgan as its chief operating officer.

Morgan will oversee the data-focused firm's global office network across India, Poland, South Africa, the UK and the US with a view to expanding its client base in clinical data services.

He joins from both Oxfordshire Life Sciences, a consulting and advisory service, where he served as managing director, and pharma services provider Concept Life sciences, which he co-founded in 2014 and served as its chief executive.

Previously, Morgan served as ICON's group president for clinical research services, and has held a number of finance management roles at AstraZeneca, Covance, GlaxoSmithKline, MDS and RPS.

David Underwood, chief executive of Quanticate, said: “Alan will be a real asset to both Quanticate and our customers as he will help to continue to optimize our processes while providing strategic direction for the future.

“As the clinical data experts, Alan's leadership over our operational teams will ensure the highest quality is delivered at all times to our customers and our leading position in the marketplace as a niche data-focused CRO is continually strengthened.”

7th October 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...